DE60205776T2 - Indolinon-derivative als protein-kinasehemmer - Google Patents
Indolinon-derivative als protein-kinasehemmer Download PDFInfo
- Publication number
- DE60205776T2 DE60205776T2 DE60205776T DE60205776T DE60205776T2 DE 60205776 T2 DE60205776 T2 DE 60205776T2 DE 60205776 T DE60205776 T DE 60205776T DE 60205776 T DE60205776 T DE 60205776T DE 60205776 T2 DE60205776 T2 DE 60205776T2
- Authority
- DE
- Germany
- Prior art keywords
- sup
- protein kinase
- kinase inhibitor
- indolinone derivative
- indolinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34374601P | 2001-12-27 | 2001-12-27 | |
| US34381301P | 2001-12-27 | 2001-12-27 | |
| PCT/US2002/041252 WO2003057690A1 (en) | 2001-12-27 | 2002-12-20 | Indolinone derivatives useful as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60205776D1 DE60205776D1 (en) | 2005-09-29 |
| DE60205776T2 true DE60205776T2 (de) | 2006-06-14 |
Family
ID=26993599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60205776T Expired - Lifetime DE60205776T2 (de) | 2001-12-27 | 2002-12-20 | Indolinon-derivative als protein-kinasehemmer |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US6686362B2 (enExample) |
| EP (1) | EP1458713B1 (enExample) |
| JP (1) | JP4363985B2 (enExample) |
| KR (1) | KR100965519B1 (enExample) |
| CN (1) | CN1290844C (enExample) |
| AT (1) | ATE302771T1 (enExample) |
| AU (1) | AU2002360753B2 (enExample) |
| BR (1) | BR0215360A (enExample) |
| CA (1) | CA2470480C (enExample) |
| CO (1) | CO5611126A2 (enExample) |
| DE (1) | DE60205776T2 (enExample) |
| DK (1) | DK1458713T3 (enExample) |
| ES (1) | ES2247411T3 (enExample) |
| HU (1) | HUP0500111A3 (enExample) |
| IL (1) | IL162203A0 (enExample) |
| MX (1) | MXPA04006271A (enExample) |
| NO (1) | NO327550B1 (enExample) |
| NZ (1) | NZ533219A (enExample) |
| PL (1) | PL208283B1 (enExample) |
| RU (1) | RU2316554C2 (enExample) |
| WO (1) | WO2003057690A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003259713A1 (en) * | 2002-08-09 | 2004-02-25 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
| EP1680401A2 (en) * | 2003-10-24 | 2006-07-19 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
| EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
| SE0401790D0 (sv) * | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| EP1951234A2 (en) | 2005-10-18 | 2008-08-06 | Janssen Pharmaceutica N.V. | Method of inhibiting flt3 kinase |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| KR101367646B1 (ko) | 2006-04-20 | 2014-02-27 | 얀센 파마슈티카 엔.브이. | Ｃ-ｆｍｓ 키나제의 저해제 |
| KR101367645B1 (ko) | 2006-04-20 | 2014-02-27 | 얀센 파마슈티카 엔.브이. | Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물 |
| US7928136B2 (en) | 2006-09-11 | 2011-04-19 | Curis, Inc. | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2521782B1 (en) | 2010-01-05 | 2019-04-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
| JP5734313B2 (ja) | 2010-01-12 | 2015-06-17 | アーべー・シオンス | チアゾールおよびオキサゾールキナーゼ阻害剤 |
| US9303046B2 (en) | 2012-08-07 | 2016-04-05 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| KR101738063B1 (ko) | 2012-09-21 | 2017-05-19 | 아로그 파마슈티칼스, 인코퍼레이티드 | 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법 |
| BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
| FR3008411B1 (fr) * | 2013-07-12 | 2015-07-03 | Servier Lab | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| WO2016016370A1 (en) | 2014-07-31 | 2016-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 receptor antagonists |
| EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| EA201991078A1 (ru) | 2016-11-02 | 2019-11-29 | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| US20200171022A1 (en) | 2017-05-17 | 2020-06-04 | Inserm (Institut National De La Santé Et Da La Recherche Médicale) | Flt3 inhibitors for improving pain treatments by opioids |
| WO2019057649A1 (en) | 2017-09-19 | 2019-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| WO2022090547A1 (en) | 2020-10-30 | 2022-05-05 | Dsm Ip Assets B.V. | Production of carotenoids by fermentation |
| US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC2096A1 (fr) * | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| TR200003514T2 (tr) | 1998-05-29 | 2002-05-21 | Sugen Inc. | Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri |
| ES2192877T3 (es) * | 1998-12-17 | 2003-10-16 | Hoffmann La Roche | 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2. |
| MXPA01006742A (es) | 1998-12-31 | 2004-04-21 | Sugen Inc | Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer. |
| DE19924401A1 (de) | 1999-05-27 | 2000-11-30 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE50012136D1 (en) | 1999-08-27 | 2006-04-13 | Boehringer Ingelheim Pharma | Substituierte indolinone als tyrosinkinase inhibitoren |
| ES2225231T3 (es) | 1999-10-06 | 2005-03-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas. |
| DE19949209A1 (de) | 1999-10-13 | 2001-04-19 | Boehringer Ingelheim Pharma | In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| WO2001042243A2 (en) | 1999-12-08 | 2001-06-14 | Advanced Medicine, Inc. | Protein kinase inhibitors |
| BRPI0117360B8 (pt) | 2000-02-15 | 2021-07-06 | Upjohn Co | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos |
| WO2002002551A1 (en) | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| BR0113356A (pt) | 2000-08-18 | 2004-04-20 | Millennium Pharm Inc | Derivados de quinazolina como inibidores de quinase |
| CA2432114A1 (en) | 2000-12-20 | 2002-07-18 | Sugen, Inc. | 4-(hetero)aryl substituted indolinones |
| AU2003259713A1 (en) * | 2002-08-09 | 2004-02-25 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
| EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
-
2002
- 2002-12-20 MX MXPA04006271A patent/MXPA04006271A/es active IP Right Grant
- 2002-12-20 DK DK02796035T patent/DK1458713T3/da active
- 2002-12-20 IL IL16220302A patent/IL162203A0/xx unknown
- 2002-12-20 KR KR1020047010148A patent/KR100965519B1/ko not_active Expired - Fee Related
- 2002-12-20 CA CA2470480A patent/CA2470480C/en not_active Expired - Fee Related
- 2002-12-20 AT AT02796035T patent/ATE302771T1/de active
- 2002-12-20 NZ NZ533219A patent/NZ533219A/en not_active IP Right Cessation
- 2002-12-20 RU RU2004122918/04A patent/RU2316554C2/ru not_active IP Right Cessation
- 2002-12-20 HU HU0500111A patent/HUP0500111A3/hu unknown
- 2002-12-20 ES ES02796035T patent/ES2247411T3/es not_active Expired - Lifetime
- 2002-12-20 CN CNB028261399A patent/CN1290844C/zh not_active Expired - Fee Related
- 2002-12-20 PL PL369602A patent/PL208283B1/pl not_active IP Right Cessation
- 2002-12-20 WO PCT/US2002/041252 patent/WO2003057690A1/en not_active Ceased
- 2002-12-20 DE DE60205776T patent/DE60205776T2/de not_active Expired - Lifetime
- 2002-12-20 BR BR0215360-2A patent/BR0215360A/pt not_active IP Right Cessation
- 2002-12-20 EP EP02796035A patent/EP1458713B1/en not_active Expired - Lifetime
- 2002-12-20 AU AU2002360753A patent/AU2002360753B2/en not_active Ceased
- 2002-12-20 JP JP2003558005A patent/JP4363985B2/ja not_active Expired - Fee Related
- 2002-12-20 US US10/327,385 patent/US6686362B2/en not_active Expired - Lifetime
-
2003
- 2003-10-22 US US10/691,094 patent/US7060703B2/en not_active Expired - Lifetime
-
2004
- 2004-07-08 NO NO20042926A patent/NO327550B1/no not_active IP Right Cessation
- 2004-07-22 CO CO04070253A patent/CO5611126A2/es not_active Application Discontinuation
-
2006
- 2006-02-21 US US11/358,305 patent/US7223783B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60205776T2 (de) | Indolinon-derivative als protein-kinasehemmer | |
| ATE339418T1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
| ATE353320T1 (de) | Tricyclische proteinkinasehemmer | |
| IL171976A0 (en) | Indazole, benzisoxazole, and banzisothiazole kinase inhibitors | |
| ATE420879T1 (de) | Indolizine als kinaseproteinhemmer | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE536353T1 (de) | 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren | |
| ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| YU61402A (sh) | Pirol substituisani 2 indolinon protein kinazni inhibitori | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| CY1112206T1 (el) | Παραγωγα πυριδαζινονης για την θεραπεια ογκων | |
| EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
| ATE473980T1 (de) | Triazolopyridazine als proteinkinase-inhibitoren | |
| DE60226469D1 (de) | Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren | |
| ATE419253T1 (de) | Inhibitoren von thienopyridin- und furopyridinkinase | |
| EA200901601A1 (ru) | Производные пиридазинона | |
| MXPA05013076A (es) | Compuestos de isoindolina-1-ona como inhibidores de cinasa. | |
| UA85394C2 (ru) | Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ | |
| DE60112742D1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| PT1268472E (pt) | Inibidores 3-aminopirazolicos de cinases dependentes da ciclina | |
| MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. | |
| ATE540951T1 (de) | Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren | |
| AU2002366563A1 (en) | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |